...
首页> 外文期刊>RSC Advances >RNA-sequencing identified miR-3681 as a negative regulator in the proliferation and migration of cervical cancer cells via the posttranscriptional suppression of HGFR
【24h】

RNA-sequencing identified miR-3681 as a negative regulator in the proliferation and migration of cervical cancer cells via the posttranscriptional suppression of HGFR

机译:RNA测序确定MiR-3681作为宫颈癌细胞通过后剖析抑制HGFR的增殖和迁移的负调节剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In this study, RNA-sequencing was used to investigate the differentially expressed miRNAs between cervical cancer tissues and matched adjacent non-tumor tissues. Five miRNAs were sharply downregulated in the cancer tissue, including miR-199a, miR-22, miR-615, miR-3681-3p (miR-3681), and miR-1193. Among them, miR-3681 was uncharacterized. The results from qPCR analysis showed that miR-3681 expression was decreased in patients with cervical cancer compared with the control, and decreased in the human cervical cancer cell lines SiHa, HeLa, C4-1, C-33A and Caski, compared with the normal human cervical epithelial cell line HCerEpic. Then, different concentrations of miR-3681 mimic and miR-3681 inhibitor were respectively transfected into the human cervical cancer cell line C-33A, and the expression of miR-3681, cell proliferation, cell apoptosis and cell migration were measured after 48 h. The results showed that the miR-3681 mimic increased the miR-3681 level, suppressed cell proliferation and migration, and induced cell apoptosis in a dose-dependent manner. In contrast, the miR-3681 inhibitor decreased the miR-3681 level, promoted cell proliferation and migration, and inhibited cell apoptosis in a dose-dependent manner. Moreover, bioinformatics analysis showed that there was a miR-3681 binding site in the mRNA 3 ' UTR of HGFR, which was robustly upregulated in cervical cancer cell lines compared with HCerEpic cells. In addition, luciferase activity analysis demonstrated that miR-3681 could directly target HGFR, which promoted the proliferation and migration of C-33A cells via activation of the PI3K/Akt pathway in a dose-dependent manner. Furthermore, our results showed that knockdown of HGFR could antagonize the promotion of anti-miR-3681 on the activation of the PI3K/Akt pathway and cell proliferation and migration. In conclusion, MiR-3681 was identified as a negative regulator in the proliferation and migration of cervical cancer cells. This function is associated with the posttranscriptional suppression of HGFR and the deactivation of the PI3K/Akt pathway.
机译:在该研究中,使用RNA测序来研究宫颈癌组织之间的差异表达的miRNA并匹配相邻的非肿瘤组织。在癌症组织中急剧下调五个miRNA,包括miR-199a,miR-22,miR-615,miR-3681-3p(miR-3681)和miR-1193。其中,MiR-3681是无表情的。 QPCR分析结果表明,与对照相比,宫颈癌患者的患者MIR-3681表达减少,与正常情况相比,人宫颈癌细胞系Siha,Hela,C4-1,C-33a和Caski中减少人宫颈上皮细胞系Hcerepic。然后,将不同浓度的miR-3681模拟和miR-3681抑制剂分别转染到人宫颈癌细胞系C-33a中,并在48小时后测量miR-3681,细胞增殖,细胞凋亡和细胞迁移的表达。结果表明,miR-3681模仿MiR-3681水平,抑制细胞增殖和迁移,并以剂量​​依赖性方式诱导细胞凋亡。相反,miR-3681抑制剂降低了miR-3681水平,促进细胞增殖和迁移,并以剂量​​依赖性方式抑制细胞凋亡。此外,生物信息学分析表明,HGFR的mRNA 3'UTR中存在miR-3681结合位点,其与宫颈癌细胞相比,在宫颈癌细胞中鲁棒地上调。此外,荧光素酶活性分析证明MIR-3681可以直接靶向HGFR,其通过以剂量依赖性方式激活PI3K / AKT途径来促进C-33A细胞的增殖和迁移。此外,我们的结果表明,HGFR的敲低可以拮抗抗miR-3681对PI3K / AKT途径和细胞增殖和迁移的激活。总之,MiR-3681被鉴定为宫颈癌细胞增殖和迁移中的负调节剂。该功能与HGFR的后术抑制和PI3K / AKT途径的失活相关。

著录项

  • 来源
    《RSC Advances》 |2019年第39期|共8页
  • 作者单位

    Xi An Jiao Tong Univ Dept Radiat Oncol Affiliated Hosp 1 277 Yanta West Rd Xian 710061 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Dept Radiat Oncol Affiliated Hosp 1 277 Yanta West Rd Xian 710061 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Dept Radiat Oncol Affiliated Hosp 1 277 Yanta West Rd Xian 710061 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Dept Radiat Oncol Affiliated Hosp 1 277 Yanta West Rd Xian 710061 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Dept Radiat Oncol Affiliated Hosp 1 277 Yanta West Rd Xian 710061 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Dept Radiat Oncol Affiliated Hosp 1 277 Yanta West Rd Xian 710061 Shaanxi Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号